Access the full text.
Sign up today, get DeepDyve free for 14 days.
H. Zaaijer, M. Koppelman, C. Farrington (2004)
Parvovirus B19 viraemia in Dutch blood donorsEpidemiology and Infection, 132
I. Thomas, M. Giambattista, C. Gérard, E. Mathys, V. Hougardy, B. Latour, T. Branckaert, Ruth Laub (2003)
Prevalence of human erythrovirus B19 DNA in healthy Belgian blood donors and correlation with specific antibodies against structural and non‐structural viral proteinsVox Sanguinis, 84
E. Heegaard, I. Jensen, J. Christensen (2001)
Novel PCR assay for differential detection and screening of erythrovirus B19 and erythrovirus V9Journal of Medical Virology, 65
Young Young, Brown Brown (2004)
Parvovirus B19N Engl J Med, 350
(2000)
Phase IV study of Plas + ® SD : hepatitis A ( HAV ) and parvovirus B 19 ( B 19 ) safety results
A. Servant, S. Laperche, F. Lallemand, V. Marinho, G. Maur, J. Meritet, A. Garbarg‐Chenon (2002)
Genetic Diversity within Human Erythroviruses: Identification of Three GenotypesJournal of Virology, 76
E. Manaresi, G. Gallinella, M. Zerbini, S. Venturoli, G. Gentilomi, M. Musiani (1999)
IgG immune response to B19 parvovirus VP1 and VP2 linear epitopes by immunoblot assayJournal of Medical Virology, 57
K. Ozawa, N. Young (1987)
Characterization of capsid and noncapsid proteins of B19 parvovirus propagated in human erythroid bone marrow cell culturesJournal of Virology, 61
M. Letaïef, G. Vanham, K. Boukef, S. Yacoub, L. Muylle, G. Mertens (1997)
Higher prevalence of parvovirus B19 in Belgian as compared to Tunisian blood donors: differential implications for prevention of transfusional transmission.Transfusion science, 18 4
J. Blümel, I. Schmidt, W. Effenberger, H. Seitz, H. Willkommen, H. Brackmann, J. Löwer, A. Eis-Hübinger (2002)
Parvovirus B19 transmission by heat‐treated clotting factor concentratesTransfusion, 42
G. Bansal, Jacqueline Hatfield, F. Dunn, A. Kramer, F. Brady, C. Riggin, M. Collett, K. Yoshimoto, S. Kajigaya, N. Young (1993)
Candidate recombinant vaccine for human B19 parvovirus.The Journal of infectious diseases, 167 5
A. Greenberg, P. Nguyen-Dinh, JonathanM. Mann, N. Kabote, R. Colebunders, H. Francis, T. Quinn, P. Baudoux, Bongo Lyamba, F. Davachi, J. Roberts, Ngandu Kabeya, J. Curran, C. Campbell (1988)
The association between malaria, blood transfusions, and HIV seropositivity in a pediatric population in Kinshasa, Zaire.JAMA, 259 4
C. Rhoades, Marc Williams, Stephen Kelsey, A. Newland (2000)
Monocyte-macrophage system as targets for immunomodulation by intravenous immunoglobulin.Blood reviews, 14 1
B. Urban, D. Ferguson, A. Pain, N. Willcox, M. Plebanski, J. Austyn, D. Roberts (1999)
Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cellsNature, 400
O. Lortholary, M. Eliaszewicz, B. Dupont, A. Couroucé (1992)
Parvovirus B19 infection during acute Plasmodium falciparum malariaEuropean Journal of Haematology, 49
K. Yoshimoto, S. Rosenfeld, N. Frickhofen, D. Kennedy, R. Hills, S. Kajigaya, N. Young (1991)
A second neutralizing epitope of B19 parvovirus implicates the spike region in the immune responseJournal of Virology, 65
E. Manaresi, G. Gallinella, A. Labate, P. Zucchelli, D. Zaccarelli, Simone Ambretti, S. Delbarba, M. Zerbini, M. Musiani (2004)
Seroprevalence of IgG against conformational and linear capsid antigens of parvovirus B19 in Italian blood donorsEpidemiology and Infection, 132
F. Scarlata, E. Gianelli, S. Miceli, L. Galimberti, S. Antinori (2002)
Acute parvovirus B19 infection and anemia during Plasmodium falciparum malaria.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 35 11
Armen Parsyan, S. Kerr, S. Owusu-Ofori, G. Elliott, J. Allain (2006)
Reactivity of Genotype-Specific Recombinant Proteins of Human Erythrovirus B19 with Plasmas from Areas Where Genotype 1 or 3 Is EndemicJournal of Clinical Microbiology, 44
M. English, Maimuna Ahmed, Clement Ngando, J. Berkley, A. Ross (2002)
Blood transfusion for severe anaemia in children in a Kenyan hospitalThe Lancet, 359
J. Allain, D. Candotti, K. Soldan, F. Sarkodie, B. Phelps, C. Giachetti, V. Shyamala, F. Yeboah, M. Anokwa, S. Owusu-Ofori, O. Opare-Sem (2003)
The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana.Blood, 101 6
J. Summers, S. Jones, M. Anderson (1983)
Characterization of the genome of the agent of erythrocyte aplasia permits its classification as a human parvovirus.The Journal of general virology, 64 (Pt 11)
Chuan-ging Wu, B. Mason, J. Jong, D. Erdman, Laurel Mckernan, Meredith Oakley, M. Soucie, B. Evatt, M. Yu (2005)
Parvovirus B19 transmission by a high‐purity factor VIII concentrateTransfusion, 45
E. Santagostino, P. Mannucci, A. Gringeri, A. Azzi, M. Morfini (1994)
Eliminating parvovirus B19 from blood productsThe Lancet, 343
A. Azzi, E. Manaresi, K. Zakrzewska, R. Desantis, M. Musiani, M. Zerbini (2004)
Antibody response to B19 parvovirus VP1 and VP2 linear epitopes in patients with haemophilic arthritisJournal of Medical Virology, 72
E. Heegaard, K. Qvortrup, J. Christensen (2002)
Baculovirus expression of erythrovirus V9 capsids and screening by ELISA: Serologic cross‐reactivity with erythrovirus B19Journal of Medical Virology, 66
C. Menéndez, A. Fleming, P. Alonso (2000)
Malaria-related anaemia.Parasitology today, 16 11
T. Pumarola (1995)
[Parvovirus B19].Medicina clinica, 104 1
Quang Nguyen, C. Sifer, V. Schneider, F. Bernaudin, Véronique Auguste, A. Garbarg‐Chenon (1998)
Detection of an erythrovirus sequence distinct from B19 in a child with acute anaemiaThe Lancet, 352
G. Kurtzman, B. Cohen, A. Field, R. Oseas, R. Blaese, N. Young (1989)
Immune response to B19 parvovirus and an antibody defect in persistent viral infection.The Journal of clinical investigation, 84 4
H. Lehmann, A. Knöll, R. Küster, S. Modrow (2003)
Frequent infection with a viral pathogen, parvovirus B19, in rheumatic diseases of childhood.Arthritis and rheumatism, 48 6
S. Owusu-Ofori, J. Temple, F. Sarkodie, M. Anokwa, D. Candotti, J. Allain (2005)
Predonation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resource‐poor settingsTransfusion, 45
Y. Yoto, T. Kudoh, K. Haseyama, N. Suzuki, Takanori Oda, T. Katoh, Tsuneo Takahashi, Sadami Sekiguchi, Shunzo Chiba (1995)
Incidence of human parvovirus B19 DNA detection in blood donorsBritish Journal of Haematology, 91
D. Candotti, N. Etiz, Armen Parsyan, J. Allain (2004)
Identification and Characterization of Persistent Human Erythrovirus Infection in Blood Donor SamplesJournal of Virology, 78
E. Grilli, M. Anderson, T. Hoskins (1989)
Concurrent outbreaks of influenza and parvovirus B19 in a boys' boarding schoolEpidemiology and Infection, 103
K. Hokynar, M. Söderlund-Venermo, M. Pesonen, A. Ranki, O. Kiviluoto, E. Partio, K. Hedman (2002)
A new parvovirus genotype persistent in human skin.Virology, 302 2
M. Söderlund, C. Brown, Willy Spaan, L. Hedman, Klaus Hedman (1995)
Epitope type-specific IgG responses to capsid proteins VP1 and VP2 of human parvovirus B19.The Journal of infectious diseases, 172 6
M. Anderson, S. Jones, S. Fisher-Hoch, E. Lewis, S. Hall, C. Bartlett, B. Cohen, P. Mortimer, M. Pereira (1983)
HUMAN PARVOVIRUS, THE CAUSE OF ERYTHEMA INFECTIOSUM (FIFTH DISEASE)?The Lancet, 321
J. Gorlin (2005)
Predonation testing of potential blood donors in resource‐restricted settingsTransfusion, 45
T. Saikawa, S. Anderson, M. Momoeda, S. Kajigaya, N. Young (1993)
Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regionsJournal of Virology, 67
R. Phillips, G. Pasvol (1992)
Anaemia of Plasmodium falciparum malaria.Bailliere's clinical haematology, 5 2
Terence Chorba, P. Coccia, R. Holman, P. Tattersall, Larry Anderson, J. Sudman, N. Young, E. Kurczynski, U. Saarinen, Robyn Moir, D. Lawrence, J. Jason, B. Evatt (1986)
The role of parvovirus B19 in aplastic crisis and erythema infectiosum (fifth disease).The Journal of infectious diseases, 154 3
J. Jordan, B. Tiangco, J. Kiss, W. Koch (1998)
Human Parvovirus B19: Prevalence of Viral DNA in Volunteer Blood Donors and Clinical Outcomes of Transfusion RecipientsVox Sanguinis, 75
H. Sato, J. Hirata, N. Kuroda, H. Shiraki, Y. Maeda, K. Okochi (1991)
Identification and mapping of neutralizing epitopes of human parvovirus B19 by using human antibodiesJournal of Virology, 65
M. Blajchman, J. Bordin (1994)
Mechanisms of transfusion-associated immunosuppression.Current opinion in hematology, 1 6
S. Cotmore, P. Tattersall (1984)
Characterization and molecular cloning of a human parvovirus genome.Science, 226 4679
Parsyan Parsyan, Kerr Kerr, Owusu‐Ofori Owusu‐Ofori (2006)
Reactivity of genotype‐specific recombinant proteins of erythrovirus B19 with plasmas from genotype 1 or 3 endemic areasJ Clin Microbiol, 44
M. Tsujimura, K. Matsushita, H. Shiraki, H. Sato, K. Okochi, Y. Maeda (1995)
Human Parvovirus B19 Infection in Blood DonorsVox Sanguinis, 69
BACKGROUND: Human erythrovirus (parvovirus) B19 is transmitted by transfusion of blood, blood components, and plasma derivatives and is resistant to most viral inactivation methods. B19 genotype 3 is prevalent in Ghana, and no related clinical information is available. STUDY DESIGN AND METHODS: This study assessed the transmission of B19 genotype 3 by transfusion and the potential effect of transfused B19 antibodies in viremic recipients. Immunological aspects of B19 genotype 3 infection in children mainly transfused for acute malarial anemia were examined. Molecular and serologic methods adapted to genotype 3 were developed and used. RESULTS: Among 114 donor‐recipient pairs from Ghana, two donations contained B19 DNA and specific antibodies, and no evidence of transmission was found. B19 immunoglobulin G (IgG)–containing whole blood was transfused to 14 B19 DNA–positive recipients. Three recipients with detectable levels of IgG to B19 failed to clear viremia 1 to 2.3 months after transfusion. Ten recipients without IgG to VP2 before transfusion cleared the virus but failed to develop an immune response to B19 within 1 to 2 months after transfusion. Only 1 patient who received little specific IgG by transfusion produced detectable antibodies. CONCLUSION: Low levels of B19 genotype 3 DNA associated with specific IgG are not infectious by transfusion. Viral clearance and apparent down regulation of immune response to B19 may be related to removal of the viral antigens by transfused antibodies and/or immunomodulatory effect of transfusion.
Transfusion – Wiley
Published: Sep 1, 2006
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.